AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.

@article{Doate2016AGS16FIA,
  title={AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.},
  author={Fernando Do{\~n}ate and Arthur Raitano and Kendall Morrison and Z. G. An and Linnette Capo and Hector Avi{\~n}a and Sher Karki and Karen Morrison and Peng Yang and Jimmy Ou and Ryuichi Moriya and Yuriy Shostak and Faisal Malik and Rossana Nadell and Wendy H. Liu and Daulet Satpayev and John E Atkinson and Ingrid B. J .K. Joseph and Daniel de Souza Pereira and Pia M. Challita-Eid and David R. Stover},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 8},
  pages={1989-99}
}
PURPOSE New cancer-specific antigens are required for the design of novel antibody-drug conjugates (ADC) that deliver tumor-specific and highly potent cytotoxic therapy. EXPERIMENTAL DESIGN Suppression subtractive hybridization identified ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3 or CD203c) as a potential human cancer-specific antigen… CONTINUE READING